Nelson Advisors interviewed by CFNews for their 'Doctolib enters the UK Market' story
NA
Nelson Advisors partner Lloyd Price was interviewed by CFNews for their 'Doctolib enters the UK Market' story.
CFNEWS (Corporate Finance News) is the leading independent digital media and data provider dedicated to the French corporate finance, private equity, and M&A ecosystem.
Founded in 2007, it has established itself as the "Gold Standard" for professionals tracking deal flow in the French-speaking market.
Core Focus Areas
The publication covers a broad spectrum of the financial landscape, specifically targeting:
Private Equity: Extensive coverage of LBOs (Leveraged Buyouts), growth capital (Capital Développement), and venture capital (Capital Innovation).
M&A: Detailed reporting on mergers, acquisitions, and corporate divestitures across all sectors.
'To be able to serve general practitioners with software, you need to have all the NHS certifications. And we are the first EPR (Electronic Patient Record) provider in England to have obtained them all in the last 25 years." “For Lloyd Price of Nelson Advisors, a British boutique specializing in M&A transactions in the healthtech sector, ‘what Doctolib has acquired is infrastructure, and speed. Doctolib is the train, and now they can go very fast because they have the tracks.’ The London-based company assures that it will continue to operate with its British teams under the leadership of its CEO, Emile Axelrad, who until now held a controlling stake in the startup through his personal holding company, Axe Ventures Ltd.
The final step before the IPO?”
With 3,000 employees, Doctolib already serves over 520,000 healthcare professionals, including 40,000 general practitioners, and 90 million patients in Europe. The French Tech champion announced it will achieve profitability for the first time in 2025. It also claims 30% growth and €422 million in ARR for the same year. Its valuation, at €5.8 billion in 2022, was, however, revised downward to €3.6 billion during a secondary funding round in April 2026.
What external growth strategy does Doctolib pursue now? Its main competitor, the Polish company DocPlanner, funded by Goldman Sachs, Piton Capital, and Point Nine, already operates in 13 countries in Europe and Latin America. This expansion into the UK could, in any case, constitute a final capital step towards an IPO. "In my opinion, it's the last piece of the puzzle," says Lloyd Price.